Evidence for Positive Selection Driving the Evolution of HIV-1 env under Potent Antiviral Therapy  by Frost, Simon D.W. et al.
d
C
6
Virology 284, 250–258 (2001)
doi:10.1006/viro.2000.0887, available online at http://www.idealibrary.com onEvidence for Positive Selection Driving the Evolution of HIV-1 env under Potent Antiviral Therapy
Simon D. W. Frost,*,†,1 Huldrych F. Gu¨nthard,‡ Joseph K. Wong,†,§ Diane Havlir,†
Douglas D. Richman,† and Andrew J. Leigh Brown*,†
*Centre for HIV Research, Institute for Cell, Animal and Population Biology, University of Edinburgh, Scotland; †University of California, San Diego,
California 92103; ‡University Hospital of Zurich, Department of Internal Medicine, Division of Infectious Diseases, Zurich, Switzerland;
and §San Diego Veterans Affairs Healthscience Center, San Diego, California
Received August 8, 2000; returned to author for revision January 31, 2001; accepted February 25, 2001
In HIV-infected individuals treated with potent antiretroviral therapy, viable virus can be isolated from latently infected cells
several years into therapy, due to the long life of these cells, ongoing replication replenishing this population, or both. We have
analysed the V3 region of the HIV-1 env gene isolated from six patients who have undergone 2 years of potent antiretroviral
therapy without frank failure of viral suppression. We show that in two (and possibly three) patients, the sequence changes
between baseline virus and virus isolated from infected cells persisting 2 years into infection result from positive selection
driving adaptive evolution, occurring either prior to or during therapy. Our analyses suggest low-level replication despite
absence of drug resistance due to drug sanctuary sites, or to low-level ongoing replication in the presence of alterations in
the selective environment during therapy, perhaps due to a decline in HIV-specific immune responsiveness or changes in
target cell pools. In one patient, genetic divergence between baseline plasma and infected cells isolated during therapy may
reflect the long half-life of some of these persistent cell populations and the divergence of viral subpopulations that occurred
prior to therapy. © 2001 Academic Press
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Although the use of highly active anti-retroviral therapy
(HAART) to suppress HIV replication can result in dra-
matic reductions in viral load, viable virus can be isolated
from latently infected cells even after several years of
HAART, suggesting that therapy may have to be main-
tained for many years to eradicate HIV from the body
(Wong et al., 1997; Finzi et al., 1997; Chun et al., 1997).
This persistence may be due to the long life of latently
infected cells, ongoing replication that replenishes the
infected cell pool, or both (Finzi et al., 1999; Zhang et al.,
1999). Even in patients that respond well to therapy, there
is substantial variation between patients in their re-
sponse to HAART, with some individuals showing a
slower decline of plasma virus early in therapy and the
intermittent reappearance plasma virus late into infec-
tion (Gu¨nthard et al., 1999). These differences may reflect
between-patient variation in levels of replication and/or
differences in which cell subpopulations are infected. It
has been suggested that activating the immune system
may increase turnover of these latently infected cells and
hence result in shorter times to eradication and reduc-
tion in the duration of HAART required. Understanding
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250the mechanism whereby HIV persists in the body and the
extent to which the virus can evolve during potent anti-
viral therapy is central to understanding how different
individuals may respond to such an intervention.
Gu¨nthard et al. (1999) analysed the divergence of the
C2–V3 region of HIV-1 env between baseline plasma
virus and virus isolated from latently infected cells from
six infected individuals. Even though all six patients had
responded well to therapy, there was wide variation in
the genetic divergence between baseline and year 2-iso-
lated virus. To address whether this divergence had
originated prior to or during therapy, the positions of the
most common recent ancestors (MRCAs) for the plasma
virus and the year 2-isolated virus were analysed. In two
patients studied, A and B, baseline and year 2-isolated
virus appeared to be very similar. In two patients, K and
L, year 2-isolated virus appeared to diverge from base-
line virus prior to therapy, suggesting that at least some
of the genetic divergence seen between baseline virus
and year 2-isolated virus originated prior to therapy. In
two other patients, C and M, year 2-isolated virus ap-
peared to diverge directly from baseline virus. As only
one sample prior to therapy and one sample during
therapy were available, the estimated positions of the
MRCAs may be inaccurate, and hence the amount of
divergence that occurred prior to therapy relative to dur-
ing therapy is difficult to establish. However, a positive
correlation was found between divergence and the
amount of residual replication that occurred during ther-
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251POSITIVE SELECTION ON HIV-1 env DURING POTENT THERAPYapy, consistent with ongoing replication playing a role in
the divergence of env in chronically infected individuals.
he findings of Zhang et al. (1999), who described pa-
tients starting treatment during early phases of infection,
were consistent with these observations.
To further address the effect of potent therapy on the
evolution of HIV-1 env and what this may tell us about the
echanism of persistence of HIV during therapy, we
ave analysed the pattern of amino acid divergence
uring therapy. We show that positive selection had
riven adaptive evolution of env in two out of six patients
tudied. We argue that a combination of positive selec-
ion prior to (or in the early stages of) therapy and the
low turnover of the latently infected cell pool are very
mportant mechanisms of generating amino acid diver-
ence between plasma virus sampled at the initiation of
herapy and virus isolated late into therapy, regardless of
hether ongoing replication occurs during therapy. As
ositive selection had driven the multiple amino acid
ifferences between baseline virus and year 2-isolated
irus, they must have had a phenotypic effect on the virus
n terms of replication rate, cell tropism, or immune
ecognition. Hence the virus that may emerge on failure
f therapy or during stimulation of the immune system
ay have different biological properties than that seen
n initiation of therapy.
RESULTS
airwise analysis of nucleotide diversity and net
ivergence
The genetic variation in the V3 region of env in the
ample of viruses isolated 2 years into HAART was
ower than that seen in plasma virus at the initiation of
herapy (Table 1). For five out of the six patients,
enetic diversity in the year 2-isolated virus was very
ow (0–0.3%), whereas for patient M some diversity
1.07%) appeared to be maintained. Phylogenetic trees
llustrating the relationship between sequences sam-
T
Diversity and Divergence
Patient
Total diversity
dt, %
Initial diversity
dx, %
D
A 3.43 6 0.59 5.07 6 0.83
B 0.20 6 0.07 0.41 6 0.15
C 2.87 6 0.52 3.96 6 0.66
K 2.08 6 0.51 0.43 6 0.18
L 1.28 6 0.18 1.49 6 0.15
M 5.34 6 0.81 3.58 6 0.66
Note. All distances were estimated using the method of Nei and Jin
errors estimated from 1000 bootstrap replicates.led at the beginning of therapy and after 2 years of
herapy are shown in Fig. 1.
w
lThe average pairwise genetic divergence between
aseline and year 2-isolated virus was greater than zero
nd varied greatly between patients. This observation by
tself does not prove that the baseline virus and year
-isolated virus came from two genetically distinct pop-
lations, as two samples taken from the same (geneti-
ally heterogeneous) population can be divergent from
ach other. Hence we estimated the “net divergence”
etween baseline and year 2-isolated virus, which cor-
ects for this effect by taking into account within-sample
iversity. If dxy is the average genetic divergence be-
tween two populations, x and y, and dx and dy are the
enetic diversities within populations x and y, respec-
ively, net divergence, da, is given by the expression da 5
xy 2 (dx 1 dy)/2. Although net divergence can be neg-
tive when the true divergence between populations is
ow, we are concerned with high levels of divergence, for
hich net divergence gives a much better indication than
ncorrected distances. Net divergence was even more
ariable than uncorrected variation, with patients B and L
xhibiting low levels of net divergence (,1%), A and C
xhibiting medium levels of net divergence (c. 1.5%), and
atients K and M exhibiting very high (.3%) levels of net
ivergence. These results show that the samples of
aseline virus and year 2-isolated virus come from ge-
etically distinct populations and are the most distinct in
atients K and M.
The low diversity seen in the viral isolates could be
ue either to the low numbers of infected cells that exist
fter 2 years of therapy or to an artifact due to sampling
very small number of infected cells during viral isola-
ion, in which case the diversity seen in the isolate may
nderestimate the true diversity in the latently infected
ell pool. In a study of lymph-node RNA in patients with
ong-term viral suppression during therapy (which in-
luded some of the patients analysed here), Gunthard et
l. (2001) showed that there were essentially no differ-
nces between sequences obtained from lymph-node
NA and those obtained from cultured cells. Patient B,
ates for the Six Patients
during therapy,
dy, %
Total divergence
dxy, %
Net divergence
da, %
0 6 0.00 3.98 6 0.74 1.44 6 0.45
5 6 0.04 0.23 6 0.08 0.00 6 0.00
2 6 0.08 3.61 6 0.72 1.57 6 0.48
0 6 0.12 3.72 6 0.98 3.36 6 0.99
5 6 0.06 1.71 6 0.32 0.84 6 0.31
7 6 0.30 7.75 6 1.30 5.42 6 1.13
corrected using a Kimura (1980) two-parameter model, with standardABLE 1
Estim
iversity
0.0
0.0
0.1
0.3
0.2
1.0ho showed very low diversity in the virus isolated from
atent cells, also showed very low diversity in sequences
initiati
idpoints
252 FROST ET AL.derived from lymph-node RNA. These observations ar-
FIG. 1. Phylogenetic trees used for the test for selection for each pa
patient M. Open circles denote sequences derived from plasma at the
cells after 2 years of suppressive therapy. Trees are rooted at their mgue that the diversity seen in viral sequences obtained
may indeed be representative of that in vivo. However, itshould be noted that even if therapy is assumed to
A) patient A, (B) patient B, (C) patient C, (D) patient K, (E) patient L, (F)
on of therapy. Closed circles denote sequences derived from infected
. Identical sequences have been removed for clarity.tient: (have no effect on sample diversity, net divergence is
still extremely high for patients K (3.29%) and M (4.17%),
a x2 ap
253POSITIVE SELECTION ON HIV-1 env DURING POTENT THERAPYwhereas for the other patients, net divergence is very low
or even negative (A, 21.09%; B, 20.18%; C, 20.35%; L,
0.22%). Under the conservative assumption that viral di-
versity is unaffected by therapy, there is no evidence of
mutational differences between the baseline virus and
year 2-isolated virus populations in patients A, B, C, and
L, but there is strong evidence of divergence in patients
K and M.
Comparing the ratio of replacement to silent changes
(dn/ds) between time points with a background
provides evidence for selection
Having established that the baseline virus and year
2-isolated virus form two distinct populations in at least
two patients, K and M, we wished to explore whether the
divergence between the two populations had been gen-
erated under similar selection pressures to those which
generated diversity within each population. Using a max-
imum-likelihood approach, we tested whether the ratio of
nonsynonymous to synonymous substitutions, dn/ds, be-
tween time points was significantly different from dn/ds
within time points.
Specifically, we asked whether the branch in the phy-
logeny representing the net divergence between the two
time points was associated with different dn/ds relative
to the background dn/ds ratio estimated using the other
branches in the phylogeny. For each patient, twice the
difference in the likelihood score of the full model (two
dn/ds ratios, “model 2”) and the simple model (one dn/ds
T
Parameter Estimates and Log-Likelihood Scores Under Model 1 (dn/
all branches), and Model 2 (dn/ds ratio different for th
Model No. of dn/ds rates A
1 One k 5 2.897 k 5 3.6
dn/ds 5 0.838 dn/ds 5
ln L 5 2859.780 ln L 5
1* dn/ds 5 1 k 5 2.936 k 5 3.5
dn/ds 5 1 dn/ds 5
ln L 5 2859.956 ln L 5
2 Two k 5 2.898 k 5 3.6
dn1/ds1 5 0.898 dn1/ds
dn2 5 0.0000 dn2 5
ds2 5 0.0166 ds2 5
ln L 5 2858.518 ln L 5
2Dln L (1* vs. 1) 0.352 0
2Dln L (2 vs. 1) 2.524 0
P value (2 vs. 1) (x2 approx.) 0.112 0
P value (2 vs. 1) (bootstrap) 0.1 0
Note. P values for the likelihood ratio test were calculated using
significance using a 2 unit of support criterion.ratio, “model 1”) was compared to the difference in like-
lihood for 100 simulated datasets produced assumingone dn/ds ratio. This allowed us to determine whether
the observed dn/ds ratio between the samples is greater
than expected by chance alone. To compare the patterns
seen in patients K and M with those found in patients
with relatively little amino acid divergence between time
points, we also analysed patients A, C, and L. The vari-
ation seen in patient B was too low for a reliable analysis
of this type, but given that viral sequences from lymph-
node RNA sampled after 1 and 2 years of therapy also
showed very low diversity (Gunthard et al., 2001), it
seems unlikely that any replication or evolution occurred
in this patient.
Fitting of model 2 to the data revealed that dn/ds
between baseline plasma virus and year 2-isolated virus
was significantly higher than dn/ds within populations for
patients K and M, with patient L approaching statistical
significance (Table 2 and Fig. 2). For all three of these
patients, the estimate of the proportion of silent changes,
ds, for the branch connecting the samples was zero,
whereas the estimates of the proportion of replacement
changes were high (1.17% in patient L, 3.34% in patient M,
and 4.25% in patient K). These results suggest that in
patients K and M (and possibly patient L, although the
results only border on statistical significance), positive
selection was responsible for generating the genetic
divergence between plasma virus and year 2-isolated
virus, rather than divergence evolving under similar se-
lection pressures to those within populations. Here we
define positive selection as that which can generate
o equal for all branches in the phylogeny), Model 1* (dn/ds 5 1 for
ch separating the baseline and year 2-isolated virus)
Patient
K L M
k 5 8.420 k 5 2.545 k 5 3.177
dn/ds 5 1.015 dn/ds 5 0.323 dn/ds 5 0.661
77 ln L 5 2555.496 ln L 5 2646.937 ln L 5 2835.867
k 5 8.409 k 5 2.725 k 5 3.286
dn/ds 5 1 dn/ds 5 1 dn/ds 5 1
34 ln L 5 2555.497 ln L 5 2658.312 ln L 5 2836.805
k 5 8.484 k 5 2.546 k 5 3.168
33 dn1/ds1 5 0.356 dn1/ds1 5 0.281 dn1/ds1 5 0.544
dn2 5 0.0425 dn2 5 0.0117 dn2 5 0.0334
ds2 5 0.0000 ds2 5 0.0000 ds2 5 0.0000
94 ln L 5 2551.955 ln L 5 2645.352 ln L 5 2833.234
0.001 22.751* 1.876
7.082* 3.169 5.266*
0.008 0.075 0.022
0.02 0.08 0.04
proximation and using parametric bootstrapping. Asterisks indicateABLE 2
ds rati
e bran
C
39
1.393
2774.4
75
1
2774.8
396
1 5 1.3
0.0071
0.0000
2774.1
.713
.567
.451
.54adaptive amino acid changes, such as mutations which
aid immune escape or increase replication.
w
w
d
l
f positiv
254 FROST ET AL.Identification of clustered amino acid substitutions
between plasma and year 2-isolated virus
To suggest a possible positive selective force, we
determined which amino acid sites were divergent be-
tween the virus sampled at initiation of therapy and those
sampled during therapy by reconstructing the nucleotide
sequences at either end of the phylogenetic branch
connecting the baseline plasma virus sequences and the
year 2-isolated virus sequences (Fig. 3), using a maxi-
mum likelihood method. It was found that these se-
quences could be reconstructed with a high degree of
confidence. We then translated the predicted nucleotide
sequence to give a predicted amino acid sequence. With
one exception (one synonymous change in patient A), all
nucleotide differences between the predicted baseline
sequence and the predicted year 2 sequence resulted in
amino acid changes.
Amino acid replacements did not appear to be uni-
formly distributed along the sequence. To test whether
this clustering was statistically significant, we compared
the length of sequence over which substitutions were
found with 100,000 datasets generated by randomising
FIG. 2. Null distribution of the likelihood ratio statistic (LRS) for the tes
that the ratio of nonsynonymous to synonymous substitutions between
distribution of the LRS is shown, and the LRS is obtained from the data. I
have a difference in likelihood score greater than that of the data.the positions of the substitutions. The position of variable
sites between the reconstructed sequences was alsocompared to the known 3D structure of the envelope
(Kwong et al., 1998).
In patient M, nine substitutions were observed over a
stretch of amino acids 34 amino acids long. The median
length over which nine amino acid substitutions were
seen in the randomised sequence was 96 residues,
significantly longer than observed (P 5 0.00023), show-
ing that amino acid substitutions were concentrated
within a relatively short region. Eight out of the nine
amino acid replacements were seen within the V3 loop.
Although changes in the V3 loop (such as the S to R
substitution in residue 11 of the loop seen in patient M)
have been associated with changes in coreceptor usage,
an in vitro MT-2 assay revealed that there was no de-
tectable switch in usage (Gu¨nthard et al., 1999). There
as also a change in a glycosylation site in the V3 loop
hich is normally conserved.
In patient K, 10 substitutions were seen over 73 resi-
ues, which approached statistical significance (median
ength 5 97, P 5 0.062). This P value is higher than that
seen in patient M as our statistical test is sensitive to
outlying mutations such as the two replacements seen
sitive selection. The LRS measures the improvement in fit by assuming
oints is greater than that within time points. For each patient, the null
e selection has occurred, then fewer than 5% of the simulations shouldt for po
time ptoward the C2 end of the sequence. Eight replacements
within a 28-residue stretch of sequence were found to-
es by “g
255POSITIVE SELECTION ON HIV-1 env DURING POTENT THERAPYward the V4 end of the sequence, and three of these
clustered in the exposed E loop were shown by Kwong et
al. (1998). No substitutions associated with a switch in
coreceptor usage were seen.
In patient L, 3 substitutions were observed over 27
residues. Although these substitutions occurred over a
shorter region than the randomised datasets (median
length 5 55), this was not statistically significant (P 5
0.147). However, the power of the test is low for so few
mutations. Two of these three mutations occurred in an
alpha helix; three mutations in this region were also seen
in patient K.
Our analyses provide support for clustered amino acid
changes between plasma and year 2-isolated virus
which, as they have arisen due to positive selection,
must have had some effect on the biological properties
of the virus. However, we could not determine the selec-
tive agent involved in driving divergence and what effect
these mutations may have on the virus.
DISCUSSION
In two patients out of six studied, K and M (and pos-
sibly in a third, L), we have demonstrated that positive
selection is responsible for generating extensive genetic
divergence in the V3 region of the env gene between
plasma virus and virus isolated from infected cells which
persisted 2 years into antiviral therapy. Our ability to
detect selection comes from our approach of using the
pattern of genetic variation within time points as an
internal control for each patient. A common test for pos-
itive selection is to ask whether the ratio of the rate of
FIG. 3. Reconstructed sequences for the branch separating plasma s
in different typefaces based upon the predicted secondary structure p
and bold 5 loop. The V3 loop is marked by asterisks, glycosylation sit
by “p.”nonsynonymous to synonymous substitution, dn/ds, is
greater than 1. This test has identified the presence ofpositive selection in the C2–V3 region of env in a number
of studies (Simmonds et al., 1990; Wolfs et al., 1992;
Cichutek et al., 1992; Bonhoeffer et al., 1995; Liu et al.,
1997; McDonald et al., 1997; Yamaguchi and Gojobori,
1997). However, this test often fails to detect positive
selection as the presence of conserved sites within a
sequence can hide positive selection on a few sites
(Nielsen and Yang, 1998). Crandall et al. (1999) demon-
strated convergent evolution of the protease gene be-
tween individuals on protease therapy, a signature of
positive selection; however, dn/ds did not differ signifi-
cantly from 1. This approach also failed to detect selec-
tion in our dataset. When we compared the dn/ds ratio
estimated from all the sequences (Model 1) with a value
of 1, there were no significant deviations for patients A, C,
K, and M, and the dn/ds ratio was significantly less than
1 for patient L (Model 1*, Table 2).
As selection appears to have resulted in multiple
amino acid substitutions, at least some of these substi-
tutions must have some adaptive effect on the biological
properties of the virus. One potential agent of positive
selection is a switch in coreceptor usage from the CCR5
to the CXCR4 molecule. This has been shown to result in
an excess of amino acid replacements relative to silent
substitutions (Yamaguchi and Gojobori, 1997, 2000).
However, no evidence for such a switch in usage was
detected in vitro for patient M (Gu¨nthard et al., 1999), and
no amino acid changes associated with CXCR4 usage
were detected for patient K.
A commonly cited cause of divergence of env is im-
mune selection. However, the reduction in viremia and
ces (AP-MP) and isolate sequences (AV-MV). Variable sites are shown
d by Kwong et al. (1998); underline 5 alpha helix; italic 5 beta sheet;
,” and sites in the loop associated with changes in coreceptor usageequen
roposethe resulting decrease in the levels of anti-HIV immunity
(Pitcher et al., 1999) may make selection by the immune
256 FROST ET AL.system less powerful during therapy and hence less
likely to drive divergence. It is possible that immune
selection drove divergence prior to therapy, although no
data were available to test this hypothesis.
There is no plausible biological mechanism whereby
the anti-retroviral drugs used in these patients may di-
rectly select for particular variants of env. However,
drugs may indirectly select for viruses in drug sanctuar-
ies, subpopulations where antiviral drugs have a subop-
timal effect and where cycles of replication can continue
during therapy. If certain amino acid substitutions were
required to infect such a sanctuary, we might expect to
see amino acid divergence between plasma virus at the
initiation of therapy and isolated virus late into therapy if
the drug sanctuary site was seeded before the initiation
of therapy.
A shift in env genetic variation, similar to those seen in
patients K and M, has been observed in two studies of
suboptimal protease therapy. In contrast to this study,
these shifts in envelope coincided with the emergence of
drug resistance. By measuring env variation using a
heteroduplex mobility assay, Delwart et al. (1998) found
that in one individual studied, a new variant of env arose
very early on in therapy, which was later replaced by an
env variant which was similar to the variant present prior
to therapy. Using a sequencing-based approach, Nijhuis
et al. (1998) demonstrated a similar phenomenon in one
patient out of five studied, with a divergent env variant
emerging early (52 days) into therapy, which was later
(84 days into therapy) replaced by variants closely re-
lated to the pretreatment strains. In these two cases, the
emerging divergent env type is so divergent and
emerged so quickly, it must have existed prior to therapy,
and was linked to resistance mutations, probably in an
anatomical compartment which was relatively isolated
from the effects of the drug. In contrast to the patterns
seen in patient K and M, the divergent env type is re-
placed by the reemergence of the original env variant,
probably through recombination between resistance mu-
tations and selection for the original env variant. The
maintenance of divergent virus over several years in
patients K and M suggests that recombination may occur
at a lower rate during potent therapy than suboptimal
therapy. In addition, selection for the baseline env variant
may not act as strongly, due to the majority of virus being
present in latently infected cells and the waning of the
immune response during therapy.
The most parsimonious explanation for the divergence
seen between plasma virus and isolated virus is that
positive selection acted on the envelope prior to or dur-
ing the early stages of therapy, but that due to the slow
rate of turnover of latently infected cells, the positively
selected env variant seen in the blood had not reached
high levels in the latently infected cells at the time of
initiation of therapy. Hence even if no ongoing replication
had occurred during therapy, a large number of aminoacid substitutions may be seen between plasma virus
and virus isolated from latently infected cells. The inher-
ent variability between individuals in patterns of selec-
tion on env will generate different levels of divergence
between plasma virus and virus in latently infected cells.
Consequently, to determine whether ongoing replication
is occurring due to therapy using sequence data, it is
necessary to measure divergence in latently infected
cells at several time points. In the case of patient A and
one other patient not included in this study, we also had
time-zero viral isolates available and these more closely
resembled one or more plasma sequences than they did
the isolates at year 2. This suggests that although sam-
ples from infected cells were not obtained for all patients
at the beginning of therapy, the effects from time of
sampling may be more important than differences be-
tween plasma and infected cells at a given time. We also
note that the two patients that exhibited multiple amino
acid substitutions, K and M, also exhibited intermittent
peaks of viremia during therapy.
In summary, we have shown that in two (and possibly
three) cases of patients on potent antiviral therapy with-
out frank failure of suppression, the sequence changes
between baseline virus and virus isolated from infected
cells persisting 2 years into infection result from positive
selection occurring either prior to or during therapy. In
these patients, the analyses suggest low-level replica-
tion despite absence of drug resistance due to sanctuary
sites, or to low-level ongoing replication in the presence
of alterations in the selective environment during ther-
apy, perhaps due to a decline in HIV-specific immune
responses or changes in target cell pools. In one of
these patients, K, the findings may alternatively reflect
the long half-life of some of these persistent cell popu-
lations and the divergence of viral subpopulations that
occurred prior to therapy. Understanding the basis of
viral persistence in the face of potent anti-retroviral ther-
apy will be extremely important for the development of
strategies for phasing out HAART in patients showing
optimum response to therapy.
METHODS
Subjects and clinical background
Six subjects were chosen from a cohort of HIV-infected
patients who had undergone two years of treatment with
indinavir, lamivudine, and zidovudine as described pre-
viously (Wong et al., 1997; Gulick et al., 1998; Gu¨nthard et
al., 1999). By conventional measures, all six patients
responded well to therapy, each sustaining a level of
plasma RNA below the detection limit of 50 copies/ml,
with the exception of patient M, who had 50 copies/ml on
the day of sampling for viral isolation only. Pretreatment
viral loads for each patient are as follows: A, 62,680
copies RNA/ml plasma; B, 19,200; C, 51,704; K, 39,322; L,
13,644; M, 50,030.
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The C2–V3 region of the env gene was sequenced for
baseline plasma virus and virus isolated 2 years into
therapy for each of the six patients A, B, C, K, L, and M as
described previously (Wong et al., 1997; Gu¨nthard et al.,
1999). For the purposes of our analyses, the ends of
sequences were edited to give an alignment of 117
codons to allow meaningful comparisons between indi-
viduals. The number of sequences obtained at baseline
and after 2 years for each patient are as follows: A (10, 9);
B (10, 13); C (10, 10); K (7, 10); L (9, 10); and M (10, 7). The
GenBank Accession Nos. for these sequences are
AF185823 to AF185937. All sequences were checked for
G to A hypermutation using the program HYPERMUT
(Rose and Korber, 2000).
Analysis of nucleotide diversity and divergence during
therapy
For each patient, we estimated the following: (i) dt, the
average pairwise nucleotide diversity for the two time
points taken together; (ii) dx, the average pairwise diver-
ity within the initial samples of plasma sequences; (iii)
y, the average pairwise diversity within the virus iso-
lates established after 2 years of potent antiretroviral
therapy; (iv) dxy, the average nucleotide divergence be-
tween the samples; and (v) da, the net nucleotide diver-
ence between the samples, which is the average diver-
ence corrected for within-sample variation using the
ethod of Nei and Jin (1989). Multiple hits were cor-
ected for using a Kimura (1980) model. Standard errors
ere estimated using 1000 bootstrap replicates. All cal-
ulations were performed using SENDBS (N. Takezaki,
ational Institute of Genetics, Mishima, Japan).
hylogenetic analysis of amino acid substitution
attern
For each patient, the tree topology was estimated
sing DNAML v.3.572c (J. Felsenstein, Department of
enetics, University of Washington), assuming a transi-
ion/transversion ratio of 2 and rate variation modeled by
sing eight rate categories taken from a discrete gamma
istribution with a shape parameter of 0.4. Codon sub-
titution models were fitted to the data and the estimated
opology using the program CODEML (Z. Yang, Depart-
ent of Biology, University College London). Codon fre-
uencies were calculated using the average nucleotide
requencies at each codon position.
One possible cause of the divergence between
lasma virus and year 2 virus is positive selection, where
mino acid changes in the envelope confer a selective
dvantage. To test for positive selection, we estimated
he rate of nonsynonymous to synonymous substitutions
dn/ds) between the two viral populations and compared
t to the estimate of dn/ds within populations. As dis-cussed by Crandall et al. (1999), estimates of dn/ds
ased on pairwise differences can be biased due to the
hylogenetic relationship between sequences. As base-
ine plasma virus and year 2-isolated virus clustered
eparately in the maximum likelihood tree obtained with
naML, we were able to use a phylogenetic test where
e estimate the dn/ds ratio for the branch connecting the
most recent common ancestor of the year 2-isolated
virus and the plasma virus (which represents the genetic
differences between the two populations, Fig. 1). To test
for differences in the selection pressure within and be-
tween viral samples, we estimated dn/ds under two
models. Model 1 assumed that the dn/ds ratio is the
same for all branches in the phylogeny (Goldman and
Yang, 1994). Model 2 assumes that the dn/ds ratio in the
branch connecting the year 2-isolated virus from the
plasma virus is different from that in the rest of the
phylogeny. The difference in log-likelihood between the
two models is a measure of the improvement in fit of
model 2 over model 1. The statistical significance of the
improvement in fit of model 2 over model 1 was estab-
lished by comparing the observed improvement in fit to
the fit obtained from simulated datasets (a technique
known as “parametric bootstrapping”). We used 100 sim-
ulated datasets per patient generated using the param-
eter estimates from model 1 (no difference in dn/ds) with
the program LISTTREE (Z. Yang, Department of Biology,
University College, London). Models 1 and 2 were fitted
to each of these simulated datasets to obtain a distribu-
tion of twice the difference in log-likelihood under the
null hypothesis that dn/ds between time points is the
same as within time points, to which the value estimated
from the observed dataset was compared.
Estimates of dn/ds may be unusually high in the pres-
ence of G to A hypermutation, which results in a “dead-
end” virus. As such substitutions will be found in the tips
of the phylogenetic tree, our test for selection, which
focuses on substitutions in an internal branch of the
phylogeny, and compares it with the rest, is conservative
in the presence of G to A hypermutations, which will
artificially raise the “background” dn/ds rate.
Testing for clusters of amino acid substitutions
We determined which amino acids differed between
baseline virus and year 2 virus, taking into account the
phylogenetic structure. Specifically, the ancestral codon
sequence at either end of the phylogenetic branch rep-
resenting the divergence between baseline plasma virus
and year 2-isolated virus was reconstructed for each
patient using a marginal reconstruction method.
We wished to determine whether amino acid substitu-
tions between baseline virus and year 2 virus were
clumped together. We performed a simple test where the
distance (in residues) subtended by the amino acid sub-
stitutions was compared to that expected if substitutions
RS
W
258 FROST ET AL.were scattered at random along the sequence. One
hundred thousand control datasets per patient were pro-
duced by randomising the positions of the substitutions.
The proportion of randomised datasets where amino
acid substitutions are more clumped than observed (i.e.,
subtend a shorter length of sequence) gives an estimate
of the P value. A program written in Mathematica v.3.0
(Wolfram Research) is available on request to perform
this test.
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